Gene therapy platform company Capsida Biotherapeutics announced the appointment of Chief Manufacturing Officer Rayne Waller to an expanded role as chief operating officer.
Waller will take on responsibility for functions that support daily operations and interface in addition to retaining his manufacturing responsibilities.
“Throughout his career, Rayne has demonstrated strong leadership in multiple roles across the globe, including most recently as chief manufacturing officer leading the development of our state-of-the-art manufacturing facility in Thousand Oaks,” Peter Anastasiou, Capsida’s chief executive, said in a statement. “Rayne’s appointment to COO will ensure Capsida achieves its goal of moving our technology from the lab and to patients, and will help Capsida realize the promise of gene therapy.”
Waller spent 27 years working with Amgen Inc.’s manufacturing and supply chain divisions prior to his post at Thousand Oaks-based Capsida. One of his many roles of seniority included being vice president of regional manufacturing, responsible for overseeing site operations for manufacturing facilities in Ireland and the Netherlands.
“Throughout my career in the biotechnology industry, I’ve worked to focus on the end goal of bringing therapies to patients who have no other options,” Waller said in a statement. “As COO, I look forward to working with the Capsida leadership team and our board to bring the promise of gene therapy to life.”
